Altium Announces Exclusive Partnership with Cytosurge for FluidFM Technology Distribution in North America
We are thrilled to announce Altium’s new partnership with Cytosurge, a global leader in precision technologies for single-cell research. As November 2024, Altium will distribute Cytosurge’s groundbreaking FluidFM® technology across North America, marking an exciting milestone in expanding innovative research tools to scientists and labs focused on single-cell analysis with an emphasis on gene expression profiles.
Cytosurge’s FluidFM technology offers unparalleled capabilities in live-cell manipulation, enabling researchers to explore cellular mechanisms with precision and control. Key applications include temporal single-cell profiling, which empowers scientists to conduct non-destructive cytoplasmic biopsies, keeping cells alive while gathering valuable gene expression data over time. This temporal approach provides direct insights into cellular dynamics, a significant advancement over traditional static sequencing.
This partnership enables Altium to provide North American researchers with access to FluidFM’s unique single-cell profiling, CRISPR cell line engineering, and microbiome research tools, addressing pressing research needs in cancer development, drug resistance, and disease progression. Together with Cytosurge, Altium is motivated in setting new standards for precision in life sciences, supporting scientific discoveries that improve health outcomes and patient care.
Stay tuned for more updates as we work to advance single-cell research in North America.